BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25965900)

  • 1. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
    Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
    Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
    Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
    Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
    Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.
    Mittra ES; Goris ML; Iagaru AH; Kardan A; Burton L; Berganos R; Chang E; Liu S; Shen B; Chin FT; Chen X; Gambhir SS
    Radiology; 2011 Jul; 260(1):182-91. PubMed ID: 21502381
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Toriihara A; Duan H; Thompson HM; Park S; Hatami N; Baratto L; Fan AC; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1518-1523. PubMed ID: 30850872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
    Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
    Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
    J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation between peri-anastomotic inflammatory changes and local recurrence following neoadjuvant radiochemotherapy surgery for colorectal cancer using visual and semiquantitative analysis of PET-CT data.
    Smeets P; Ham H; Ceelen W; Boterberg T; Verstraete K; Goethals I
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):327-32. PubMed ID: 20639817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.
    Chiang GC; Galla N; Ferraro R; Kovanlikaya I
    J Neuroimaging; 2017 Mar; 27(2):243-247. PubMed ID: 27515717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET.
    Kwee SA; Ko JP; Jiang CS; Watters MR; Coel MN
    Radiology; 2007 Aug; 244(2):557-65. PubMed ID: 17581887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.